12 Sep 2022 --- NovaBay Pharmaceuticals is entering into a Securities Purchase Agreement with select commercial investors in regards to a private placement of 3,250 shares of a newly created Series C non-voting convertible preferred stock at a price of US$1,000 per share. The company expects to receive a gross profit of about US$3.25 million from the private placement, which is expected to close in the fourth quarter of 2022.
